Annual Scientific Meeting

High-Risk Ulcerative Colitis – Where Do We Start?

Speaker(s)

• 

  David Rubin, MD, FACG

  Joseph B. Kirsner Professor of Medicine; Chief, Section of Gastroenterology, Hepatology and Nutrition; Co-Director, Digestive Diseases Center
  University of Chicago Medicine
  Chicago, IL, US

  Consultant: AbbVie, Abgenomics, Allergan, Inc., Arena Pharmaceuticals, Biomica, Bristol-Myers Squibb, Dizal Pharmaceuticals, Ferring Pharmaceuticals, Inc., Genentech/Roche, Janssen Pharmaceuticals, Lilly, Medtronic, Merck Co., Inc., Napo Pharmaceuticals, Pfizer, Shire, Takeda, Target PharmaSolutions, Inc.
  Grant/Research Support: AbbVie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire, Takeda
  Board of Trustees: American College of Gastroenterology
  Co-Founder: GoDuRn LLC (non-profit medical education company)
  Co-Founder, CFO: Cornerstones Health, Inc. (non-profit medical education company)

Learning Objectives:

• Discuss medication selection based on patient and disease-related factors for high-risk UC.